[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-372796-105":59,"doc-detail-372796-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enabling-access-to-genetically-modified-cell-therapies-through-flexible-approaches-to-manufacturing-and-cost-recovery","Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","","Genetically modified cell-based therapies offer transformative potential for patients with rare and ultra-rare cancers, yet regulatory approval, reimbursement, and broad access are often blocked by misaligned regulatory, manufacturing, and financial frameworks. This commentary draws on a collaborative white paper and a May 2025 public meeting to propose three strategies: flexible CMC requirements for small populations, adaptable regulatory frameworks for diverse manufacturing models, and limited cost recovery mechanisms. It highlights recent regulatory discussions aligning with these priorities, enabling timely, sustainable access in high-need settings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enabling-access-to-genetically-modified-cell-therapies-through-flexible-approaches-to-manufacturing-and-cost-recovery/372796/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enabling-access-to-genetically-modified-cell-therapies-through-flexible-approaches-to-manufacturing-and-cost-recovery/372796.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem limits access to genetically modified cell therapies?","Question",{"text":112,"@type":113},"Misalignment across regulatory, manufacturing, and financial systems prevents promising therapies from gaining approval and reaching patients, especially for rare or ultra-rare populations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What strategies does the commentary propose to enable access?",{"text":117,"@type":113},"It outlines three strategies: flexible CMC requirements for small populations, adaptable regulatory frameworks for different manufacturing models, and limited cost recovery mechanisms to bridge early gaps.",{"name":119,"@type":110,"acceptedAnswer":120},"How can CMC flexibility be achieved for small patient populations?",{"text":121,"@type":113},"The commentary suggests abbreviated stability protocols at release, supported by strong in-process controls and scientific rationale, plus alternative evidence when traditional batch comparability is infeasible.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},372796,1791396855,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Commentary  \nEnabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery  \nMark D Stewart  ,1 Christopher R Cabanski  ,2 Jeff D Allen,1 John E Connolly,2 Ben M Beneski,3 Boro Dropulić ,4 Steven A Feldman,5 Lee A Fleisher,6,7  \nPatrick J Hanley,8,9 Kristen Hege,10 Natasha Kekre  ,11 Holly Fernandez Lynch,12 Crystal L Mackall  13,14,15  \nTo cite: Stewart MD, Cabanski CR, Allen JD,  \net al. Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery. Journal for ImmunoTherapy of Cancer 2025;13:e013518 . doi:10 . 1136/ jitc-2025-013518  \nAccepted 17 November 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Mark D Stewart; [mstewart@focr.org](mstewart@focr.org)  \nABSTRACT  \nGenetically modified cell-based therapies hold transformative potential, particularly for patients with rare cancers and ultra-rare diseases. However, progress toward regulatory approval, reimbursement, and broad patient access is often constrained by misaligned regulatory, manufacturing, and financial frameworks that do not reflect the realities of treating small populations and lowthroughput production models. Drawing on a collaborative white paper and public meeting convened by Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy in May 2025, this commentary outlines three strategies to streamline regulatory pathways and enable timely, sustainable access: (1) flexible approaches to Chemistry, Manufacturing, and Controls requirements in small populations,(2) adaptable regulatory frameworks to support diverse manufacturing models, and (3) limited cost recovery mechanisms to bridge early access and development gaps. Recent regulatory and policy discussions have echoed these priorities, signaling an opportunity to align oversight with operational realities to advance innovation and access for patients in high-need settings.  \nINTRODUCTION  \nIn recent years, scientific progress in genetically modified cell-based therapies has accelerated dramatically. Innovative products such as chimeric antigen receptor T-cell and T-cell receptor therapies have demonstrated remarkable clinical potential, including inpatients with cancer who previously had few or no effective treatment options. In many cases, we are no longer waiting for the science—robust biological rationale and encouraging clinical data exist. Instead, the limiting factor is misalignment across regulatory, manufacturing, and financial systems, which each presenting distinct challenges that prevent promising therapies from achieving regulatory approval and reaching patients. As  \na result, promising therapies may be shelved despite strong clinical signals and urgent unmet need, particularly in settings that fall outside traditional biopharmaceutical development models, such as autologous therapies for low-incidence tumor types, including pediatric cancers.1 While some genetically modified cell-based therapies may begin in small, defined populations and later expand to broader indications, the challenges discussed here are most acute for therapies inherently limited to rare or ultra-rare diseases. These products often lack the opportunity to achieve scale and therefore require tailored, proportional approaches to regulatory flexibility and manufacturing feasibility.  \nTo address these barriers, Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy convened experts across the research, regulatory, academic, and patient communities to identify actionable strategies for greater regulatory flexibility, adaptable manufacturing approaches, and limited cost recovery to sustain development. These discussions informed a collaborative white paper reflecting broad alignment on","cbCaiqGdPwnlQQB1","https://ap.wps.com/l/cbCaiqGdPwnlQQB1","pdf",342423,"English","# Abstract\n# Introduction\n# CMC Flexibility in Small Populations","[{\"question\":\"What problem limits access to genetically modified cell therapies?\",\"answer\":\"Misalignment across regulatory, manufacturing, and financial systems prevents promising therapies from gaining approval and reaching patients, especially for rare or ultra-rare populations.\"},{\"question\":\"What strategies does the commentary propose to enable access?\",\"answer\":\"It outlines three strategies: flexible CMC requirements for small populations, adaptable regulatory frameworks for different manufacturing models, and limited cost recovery mechanisms to bridge early gaps.\"},{\"question\":\"How can CMC flexibility be achieved for small patient populations?\",\"answer\":\"The commentary suggests abbreviated stability protocols at release, supported by strong in-process controls and scientific rationale, plus alternative evidence when traditional batch comparability is infeasible.\"}]","Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery | PDF",1790195414,13]